Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 90
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04502030 | Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) | ||
| NCT04400058 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | ||
| NCT03866798 | Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) | ||
| NCT01863758 | Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A | ||
| NCT02278575 | Atenativ Effect on Uterine Blood Flow and Preeclampsia | ||
| NCT02256917 | Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A | ||
| NCT01365546 | Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery | ||
| NCT01313507 | High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam) | ||
| NCT04046848 | Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A | ||
| NCT02740335 | Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk. | ||
| NCT04106908 | Effectiveness and Tolerability of Eqwilate in Real-life Conditions | ||
| NCT04651400 | Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection | ||
| NCT01341912 | Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs) | ||
| NCT02972281 | Systematic Search for Primary Immunodeficiency in Adults With Infections | ||
| NCT01992549 | Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII | ||
| NCT04153422 | IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies | ||
| NCT04867837 | Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor | ||
| NCT02050841 | Octaplas Pediatric Plasma Replacement Trial | ||
| NCT01938404 | Octaplas Adult TTP Trial | ||
| NCT03939533 | Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases | ||
| NCT03686969 | Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis | ||
| NCT04411667 | Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19 | ||
| NCT02253082 | Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28) | ||
| NCT02111590 | Immunoglobulin Dosage and Administration Form in CIDP and MMN | ||
| NCT06599697 | The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy | ||
| NCT03677557 | Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment | ||
| NCT03369301 | The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency | ||
| NCT03988426 | Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases | ||
| NCT01225276 | Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP | ||
| NCT01012323 | A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases | ||
| NCT01938378 | Octaplas Pediatric Plasma Exchange Trial | ||
| NCT01859754 | Octagam 5% Versus Comparator Post Marketing Trial | ||
| NCT04508530 | Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) | ||
| NCT04354129 | Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency. | ||
| NCT02962765 | Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ | ||
| NCT01575756 | Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap | ||
| NCT03092245 | Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial | ||
| NCT01063595 | A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD | ||
| NCT01602419 | Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease | ||
| NCT04023019 | Treatment of Hemophilia A Patients With FVIII Inhibitors | ||
| NCT04053699 | Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment | ||
| NCT04534751 | Factor In the Initial Resuscitation of Severe Trauma 2 Patients | ||
| NCT04052698 | Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD | ||
| NCT03348618 | A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) | ||
| NCT04953884 | Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age | ||
| NCT05935358 | Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study | ||
| NCT03369314 | Observational Study of the Use of octaplasLG®. | ||
| NCT03695978 | Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients | ||
| NCT03656640 | Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases | ||
| NCT01349790 | Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia |
